obinutuzumab
Selected indexed studies
- Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis. (N Engl J Med, 2025) [PMID:39927615]
- Obinutuzumab as treatment for ANCA-associated vasculitis. (Rheumatology (Oxford), 2022) [PMID:34958343]
- Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN. (Blood, 2025) [PMID:40198878]
_Worker-drafted node — pending editorial review._
Connections
obinutuzumab is a side effect of
Sources
- Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN. (2025) pubmed
- Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. (2020) pubmed
- Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation. (2025) pubmed
- A tale of two antibodies: obinutuzumab versus rituximab. (2018) pubmed
- Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis. (2025) pubmed
- Obinutuzumab as treatment for ANCA-associated vasculitis. (2022) pubmed
- Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial. (2023) pubmed
- Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. (2019) pubmed
- B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. (2022) pubmed
- Obinutuzumab for the First-Line Treatment of Follicular Lymphoma. (2017) pubmed